Strategic Intelligence: Navigating shifts in pharmaceutical patent litigation
Key expert takeaways on the IRA, European court expansion, and patent delisting for life sciences leaders.
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Key expert takeaways on the IRA, European court expansion, and patent delisting for life sciences leaders.
Recently, both the FDA and EMA have raised concerns about counterfeit drug products, including GLP-1s used for weight loss and diabetes, being marketed in the...
